Patents Assigned to Pfizer Inc.
  • Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent
    Publication number: 20220071965
    Abstract: The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a benzoxazole derivative transthyretin stabilizer or a pharmaceutically acceptable salt or prodrug thereof and an additional therapeutic agent for the treatment of transthyretin amyloidosis. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or a pharmaceutically acceptable salt or prodrug thereof and one or more additional therapeutic agent for the treatment of transthyretin amyloidosis.
    Type: Application
    Filed: December 17, 2019
    Publication date: March 10, 2022
    Applicant: Pfizer Inc.
    Inventors: Christine Ellen Bulawa, James Allan Fleming
  • Chimeric antigen receptors targeting epidermal growth factor receptor variant III
    Patent number: 11267892
    Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: March 8, 2022
    Assignee: Pfizer Inc.
    Inventors: Oi Kwan Wong, Joyce Ching Chou, Mathilde Brunnhilde Dusseaux, Julianne Smith, Barbra Johnson Sasu
  • Nitrile-Containing Antiviral Compounds
    Publication number: 20220062232
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Application
    Filed: August 5, 2021
    Publication date: March 3, 2022
    Applicant: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
  • compositions and methods thereof
    Patent number: 11260119
    Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: March 1, 2022
    Assignee: Pfizer Inc.
    Inventors: Robert G. K. Donald, Annaliesa Sybil Anderson, Laurent Oliver Chorro, Jianxin Gu, Jin-Hwan Kim, Srinivas Kodali, Jason Arnold Lotvin, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, Ling Chu, Scott Ellis Lomberk, Karen Kiyoko Takane, Nishith Merchant, Wei Chen
  • SYNTHESIS OF PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES
    Publication number: 20220056025
    Abstract: This invention relates to novel methods to prepare substituted pyrido[2,3-d]pyrimidin-7(8H)-ones, and salts and stereoisomers thereof, as well as intermediates useful for the preparation of such compounds.
    Type: Application
    Filed: September 23, 2019
    Publication date: February 24, 2022
    Applicant: Pfizer Inc.
    Inventors: Adam Ross Brown, Jean-Nicolas Desrosiers, Shengquan Duan, Joel Michael Hawkins, Cheryl Myers Hayward, Mark Thomas Maloney, Sebastien Monfette, Hahdi Hakimioun Perfect, Daniel William Widlicka
  • Tofacitinib oral sustained release dosage forms
    Patent number: 11253523
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: February 22, 2022
    Assignee: Pfizer Inc.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
  • Combinations for treatment of NASH/NAFLD and related diseases
    Patent number: 11254660
    Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4?-piperidine]-1?-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: February 22, 2022
    Assignee: Pfizer Inc.
    Inventors: William Paul Esler, Trenton Thomas Ross
  • Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives
    Patent number: 11254668
    Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein variables are defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: February 22, 2022
    Assignee: Pfizer Inc.
    Inventors: Brian Stephen Gerstenberger, Andrew Fensome, Dafydd Rhys Owen, Matthew Frank Brown, Matthew Merrill Hayward, Felix Vajdos, Li Huang Xing, Stephen Wayne Wright
  • Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof
    Patent number: 11254684
    Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: February 22, 2022
    Assignee: Pfizer Inc.
    Inventors: Kapildev Kashmirilal Arora, Jacob Cole DeForest, Andrew Kevern Hills, Brian Patrick Jones, Kris Nicole Jones, Chad Arthur Lewis, Anil Mahadeo Rane
  • RECOMBINANT VACCINIA VIRUS
    Publication number: 20220033784
    Abstract: The present disclosure provides human IL-2 variants, recombinant oncolytic viruses comprising the IL-2 variant, compositions comprising the IL-2 variant or recombinant oncolytic virus, and use of the IL-2 variants, recombinant oncolytic virus, or compositions for treating cancer in an individual.
    Type: Application
    Filed: July 9, 2021
    Publication date: February 3, 2022
    Applicant: Pfizer Inc.
    Inventors: Joseph John Binder, Michael Dale Eisenbraun, Clare Lees, Jeremy Shawn Myers, James Travis Patterson
  • CRYSTALLINE FORMS OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA MALEATE
    Publication number: 20220024894
    Abstract: This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
    Type: Application
    Filed: October 6, 2021
    Publication date: January 27, 2022
    Applicant: PFIZER INC.
    Inventors: Eric Christian Hansen, Christopher Scott Seadeek, Anil Mahadeo Rane
  • CRYSTALLINE FORMS OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA MALEATE
    Publication number: 20220024893
    Abstract: This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
    Type: Application
    Filed: October 6, 2021
    Publication date: January 27, 2022
    Applicant: PFIZER INC.
    Inventors: Eric Christian Hansen, Christopher Scott Seadeek
  • Combinations For Treatment Of NASH/NAFLD And Related Diseases
    Publication number: 20220023299
    Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4?-piperidine]-1?-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.
    Type: Application
    Filed: October 11, 2021
    Publication date: January 27, 2022
    Applicant: Pfizer Inc.
    Inventors: William Paul Esler, Trenton Thomas Ross
  • Compounds and Methods for the Treatment of COVID-19
    Publication number: 20220017548
    Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
    Type: Application
    Filed: July 1, 2021
    Publication date: January 20, 2022
    Applicant: Pfizer Inc.
    Inventors: Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Martin Youngjin Pettersson, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
  • THERAPEUTIC ANTIBODIES AND THEIR USES
    Publication number: 20220017622
    Abstract: The present invention relates to antibodies that specifically bind to B7-H4 (B7 Homology 4, encoded by gene VTCN1) and bispecific antibodies that specifically bind to both B7-H4 and CD3 (Cluster of Differentiation 3), and polynucleotides, pharmaceutical compositions and methods and uses thereof.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 20, 2022
    Applicant: PFIZER INC.
    Inventors: JAMES REASONER APGAR, ANDREA THERESE HOOPER, MALGORZATA AGNIESZKA NOCULA-LUGOWSKA, LEI WU
  • Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
    Publication number: 20220016229
    Abstract: The present invention relates to new glycoconjugates comprising Streptococcus pneumoniae capsular saccharide antigens and uses thereof. Glycoconjugates of the present invention will typically comprise 2 or more saccharides antigens conjugated to the same molecule of the protein carrier. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using immunogenic compositions comprising said novel glycoconjugates.
    Type: Application
    Filed: December 9, 2019
    Publication date: January 20, 2022
    Applicant: Pfizer Inc.
    Inventors: Avvari Krishna Prasad, Jianxin Gu, Jin-Hwan Kim, Suddham Singh
  • Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors
    Patent number: 11220518
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formulas A and B: wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, virus diseases, inflammatory disorders, or diseases in which the liver is a target organ.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: January 11, 2022
    Assignee: PFIZER INC.
    Inventors: Hui Li, Seiji Nukui, Stephanie Anne Scales, Min Teng, Chunfeng Yin
  • Cyclin dependent kinase inhibitors
    Patent number: 11220494
    Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: January 11, 2022
    Assignee: Pfizer Inc.
    Inventors: Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
  • AMINOPYRIMIDINYL DERIVATIVES
    Publication number: 20220002301
    Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently hydrogen or hydroxy; wherein R1 and R2 are not both hydroxy. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
    Type: Application
    Filed: June 30, 2021
    Publication date: January 6, 2022
    Applicant: Pfizer Inc.
    Inventors: Brian Stephen GERSTENBERGER, Wenhua JIAO, Manjinder Singh LALL, Ricardo LIRA, Mark Edward SCHNUTE
  • BINDING MOLECULES TO THE HUMAN OX40 RECEPTOR
    Publication number: 20220002428
    Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
    Type: Application
    Filed: July 13, 2021
    Publication date: January 6, 2022
    Applicants: Pfizer Inc., Bristol-Myers Squibb Company
    Inventors: Jing MIN, Yanli WU, Rory F. FINN, Barrett R. THIELE, Wei LIAO, Ronald P. GLADUE, Arvind RAJPAL, Timothy J. PARADIS, Peter BRAMS, Brigitte DEVAUX, Yi WU, Kristopher TOY, Heidi N. LEBLANC, Haichun HUANG